Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifabotuzumab - Humanigen

Drug Profile

Ifabotuzumab - Humanigen

Alternative Names: Anti-EphA3 MAb; Anti-EphA3 monoclonal antibody; Humaneered antibody; IgG1-kappa antibody; IgG1K antibody; KB-004

Latest Information Update: 07 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Humanigen; Olivia Newton-John Cancer Research Institute
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; EphA3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Phase I Glioblastoma

Most Recent Events

  • 04 Jan 2019 Pharmacodynamics data from a preclinical trial in Glioblastoma released by Humanigen
  • 21 Dec 2017 Ifabotuzumab - Humanigen is available for licensing as of 21 Dec 2017. www.humanigen.com
  • 05 Dec 2017 Phase-I clinical trials in Glioblastoma in Australia (IV) (NCT03374943)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top